21 August 2019 - In response to concerns about the impact a US trade deal would have on medicine pricing, the ABPI continues to emphasise that in the UK, we have very strict rules which control medicine spend. 

Richard Torbett, Executive Director of Commercial Policy at the ABPI said:

“Pharmaceutical companies have voluntarily signed up to a five-year agreement which controls how much the NHS can spend on medicines; this will not change.

“The strict processes the UK has in place to ensure value for money mean we have some of the lowest prices for medicines in Europe and this is good for NHS patients.” 

Read ABPI Statement